CAMP4 Therapeutics Corp (CAMP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.41-1.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CAMP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance CMP-002 into a first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder, starting in multiple jurisdictions including Australia and Argentina.
Stated as a priority in 3 of last 3 quarters. Management secured regulatory clearance in Australia and Argentina and expects to initiate the Phase 1/2 clinical trial of CMP-002 in Q4 2026. The company is delivering on its stated timeline with trial initiation anticipated in the second half of 2026.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002; trial initiation anticipated in Q4 2026.”
“Received clearance from Australia's TGA and local HREC to initiate Phase 1/2 clinical trial of CMP-002.”
“CMP-002 expected to advance into a Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder in 2H 2026.”
Ensure sufficient cash and cash equivalents to fund planned activities through the end of 2028, supported by private placement proceeds.
Stated as a priority in 3 of last 3 quarters. Cash and cash equivalents were $86.4 million at 2026-Q2, down from $99 million at 2026-Q1, supplemented by $50.1 million raised in a private placement in 2026-Q2. Management is delivering on maintaining a cash runway through 2028 supported by recent financing.
“Cash runway extended through the end of 2028; $86.4 million cash as of June 30, 2026.”
“Received $50.1 million from second closing of private placement to support advancement of CMP-002.”
“Cash runway expected into 2028, with $99 million in cash and cash equivalents as of 3/31/26.”
Continue preclinical development of CMP-002, including demonstrating efficacy in seizure models and preparing for clinical trials.
Stated as a priority in 2 of last 2 quarters. Management presented preclinical data demonstrating CMP-002 improves seizure phenotypes in a SYNGAP1 mouse model, supporting its therapeutic potential. This progress aligns with plans to advance CMP-002 into clinical trials in the second half of 2026, indicating delivery on preclinical development goals.
“CMP-002 administration produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mouse model.”
“CMP-002 expected to advance into Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026.”
Over the trailing year it converted 0.89x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.